Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

997 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Development and validation of a prognostic nomogram for colorectal cancer after radical resection based on individual patient data from three large-scale phase III trials.
Honda M, Oba K, Akiyoshi T, Maeda H, Kashiwabara K, Kanda M, Mayanagi S, Aoyama T, Hamada C, Sadahiro S, Fukunaga Y, Ueno M, Sakamoto J, Saji S, Yoshikawa T. Honda M, et al. Among authors: kanda m. Oncotarget. 2017 Oct 12;8(58):99150-99160. doi: 10.18632/oncotarget.21845. eCollection 2017 Nov 17. Oncotarget. 2017. PMID: 29228760 Free PMC article.
Updated evidence on adjuvant treatments for gastric cancer.
Kanda M, Kodera Y, Sakamoto J. Kanda M, et al. Expert Rev Gastroenterol Hepatol. 2015;9(12):1549-60. doi: 10.1586/17474124.2015.1094373. Epub 2015 Sep 28. Expert Rev Gastroenterol Hepatol. 2015. PMID: 26414453 Review.
Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer.
Munemoto Y, Kanda M, Ishibashi K, Hata T, Kobayashi M, Hasegawa J, Fukunaga M, Takagane A, Otsuji T, Miyake Y, Nagase M, Sakamoto J, Matsuoka M, Oba K, Mishima H. Munemoto Y, et al. Among authors: kanda m. BMC Cancer. 2015 Oct 24;15:786. doi: 10.1186/s12885-015-1712-0. BMC Cancer. 2015. PMID: 26497654 Free PMC article. Clinical Trial.
Metastatic pathway-specific transcriptome analysis identifies MFSD4 as a putative tumor suppressor and biomarker for hepatic metastasis in patients with gastric cancer.
Kanda M, Shimizu D, Tanaka H, Shibata M, Iwata N, Hayashi M, Kobayashi D, Tanaka C, Yamada S, Fujii T, Nakayama G, Sugimoto H, Koike M, Fujiwara M, Kodera Y. Kanda M, et al. Oncotarget. 2016 Mar 22;7(12):13667-79. doi: 10.18632/oncotarget.7269. Oncotarget. 2016. PMID: 26872374 Free PMC article.
The COMET Open-label Phase II Study of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal Cancer.
Kataoka M, Kanda M, Ishigure K, Matsuoka H, Sato Y, Takahashi T, Tanaka C, Deguchi T, Shibata Y, Sato M, Inagaki H, Matsui T, Kondo A, Takano N, Tanaka H, Sakamoto J, Oba K, Kondo K. Kataoka M, et al. Among authors: kanda m. Ann Surg Oncol. 2017 Feb;24(2):546-553. doi: 10.1245/s10434-016-5557-9. Epub 2016 Sep 8. Ann Surg Oncol. 2017. PMID: 27638675 Clinical Trial.
Erratum to: The COMET Open-label Phase II Study of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal Cancer.
Kataoka M, Kanda M, Ishigure K, Matsuoka H, Sato Y, Takahashi T, Tanaka C, Deguchi T, Shibata Y, Sato M, Inagaki H, Matsui T, Kondo A, Takano N, Tanaka H, Sakamoto J, Oba K, Kondo K. Kataoka M, et al. Among authors: kanda m. Ann Surg Oncol. 2016 Dec;23(Suppl 5):1064. doi: 10.1245/s10434-016-5593-5. Ann Surg Oncol. 2016. PMID: 27646021 No abstract available.
Pharmacokinetic dose adjustment of 5-FU in modified FOLFOX7 plus bevacizumab for metastatic colorectal cancer in Japanese patients: a-JUST phase II clinical trial.
Denda T, Kanda M, Morita Y, Kim HM, Kashiwada T, Matsuda C, Fujieda S, Nakata K, Murotani K, Oba K, Sakamoto J, Mishima H. Denda T, et al. Among authors: kanda m. Cancer Chemother Pharmacol. 2016 Dec;78(6):1253-1261. doi: 10.1007/s00280-016-3184-6. Epub 2016 Nov 2. Cancer Chemother Pharmacol. 2016. PMID: 27807652 Clinical Trial.
Impact of postoperative complications on the colorectal cancer survival and recurrence: analyses of pooled individual patients' data from three large phase III randomized trials.
Aoyama T, Oba K, Honda M, Sadahiro S, Hamada C, Mayanagi S, Kanda M, Maeda H, Kashiwabara K, Sakamoto J, Saji S, Yoshikawa T. Aoyama T, et al. Among authors: kanda m. Cancer Med. 2017 Jul;6(7):1573-1580. doi: 10.1002/cam4.1126. Epub 2017 Jun 22. Cancer Med. 2017. PMID: 28639738 Free PMC article.
Randomized phase II study of daily and alternate-day administration of S-1 for advanced gastric cancer (JFMC43-1003).
Tanaka H, Kanda M, Morita S, Taguri M, Nishikawa K, Shimada M, Muguruma K, Koeda K, Takahashi M, Nakamori M, Konno H, Tsuji A, Hosoya Y, Shirasaka T, Yamamitsu S, Sowa M, Kitajima M, Okajima M, Kobayashi M, Sakamoto J, Saji S, Hirakawa K. Tanaka H, et al. Among authors: kanda m. Int J Clin Oncol. 2017 Dec;22(6):1052-1059. doi: 10.1007/s10147-017-1157-3. Epub 2017 Jun 30. Int J Clin Oncol. 2017. PMID: 28667408 Free PMC article. Clinical Trial.
997 results